

## DAFTAR PUSTAKA

1. EUCAN. EUCAN Cancer Factsheets 201: Ovary. 2018.
2. Gynecologic AC of O. number 71 The Role of the Obstetrician-Gynecologist in the Early Detection of ovarian cancer in woman at average risk 6. In: The Role of the Obstetrician-Gynecologist. 2018.
3. GLOBOCAN. Indonesia : Cancer Today. 2020;
4. Syamel M, GMA Y. Relations between the incidence of endometriosis and type 1 epithelial ovarian cancer at M Djamil Central Hospital of Padang Indonesia. 2023;12(1):119–122.
5. Iota Group. About IOTA.
6. Hidalgo J, Ros F, Aubá M, Errasti T, Olartecoechea B, Ruiz-Zambrana Á, et al. Prospective external validation of IOTA three-step strategy for characterizing and classifying adnex. Ultrasound Obs Gynecol. 2019;53(5):693-700.
7. Hoffman B, Scherge J, Halvorson L, Hamid C, Corton MS. Willams Gynecology. 4th ed. New York: Mc-Graw Hall Education; 2020.
8. Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. Oktober 2014;384(9951):1376–88.
9. Kosary CL. Figo stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: An analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol. Januari 1994;10(1):31–46.
10. Yu KH, Hu V, Wang F, Matulonis UA, Mutter GL, Golden JA, et al. Deciphering serous ovarian carcinoma histopathology and platinum response by convolutional neural networks. BMC Med. Desember 2020;18(1):236.
11. Madan R, Narula M, Chitra R, Bajaj P. Sonomorphological and color doppler flow imaging evaluation of adnexal masses. Indian J Radiol Imaging. 2004;14(5):365–72.
12. Prasad S, Jha MK, Bharat I, Sehgal C. Evaluation of Ovarian Masses by

- Color Doppler Imaging and Histopathological Correlation. *Int J Contemp Med Surg Radiol*. Juni 2019;4(2).
13. Nigam R, Gujral K, Rastogi D, Chawla D, Mansukhani C, Nayar S. International Ovarian Tumor Analysis (IOTA) Simple Rules for Classifying Ovarian Masses and Its Correlation with Histopathology. *Indian Obstet Gynaecol*. 2020;10(2):52–60.
  14. Hiett AK, Sonek JD, Guy M, Reid TJ. Performance of IOTA Simple Rules, Simple Rules risk assessment, ADNEX model and O-RADS in differentiating between benign and malignant adnexal lesions in North American women. *Ultrasound Obs Gynecol*. 2022;59(5):668-676.
  15. Antonius PA, Syamel M, Zaldy M, Putra R, Saberko S. Ovarian goiter with papillary thyroid carcinoma : A very rare case. 2022. hal. 179–83.
  16. Konar H. DC Dutta's Textbook of Gynecology. JP Medical Ltd; 2017.
  17. Force UPST. Screening for Ovarian Cancer US Preventive Services Task Force Recommendation Statement. 2018;319(6):588–94.
  18. Budiana N, Angelina MP. Ovarian cancer: Pathogenesis and current recommendations for prophylactic surgery. *J Turkish Ger Gynecol Assoc*. 2019;20:47–54.
  19. Hatano Y, Hatano K, Tamada M, Al. E. Comprehensive review of ovarian serous carcinoma. *Adv Anat Pathol*. 2019;26(5):329–36.
  20. Society AC. Ovarian Cancer Causes, Risk Factors and Prevention. 2020;
  21. Chang LC, Huang CF, Lai MS, Shen LJ, Wu FLL, Cheng W. Prognostic factors in epithelial ovarian cancer: A population-based study. *PLoS One*. 2018;13(3).
  22. Krupa K, Patel-Lippmann, Sadowski EA, Robbins, Jessica B Paroder V, Barroilhet L, Maddox E, et al. Comparison of International Ovarian Tumor Analysis Simple Rules to Society of Radiologists in Ultrasound Guidelines for Detection of Malignancy in Adnexal Cysts : Comparative Study. *AJR Am J Roentgenol*. 2020;214(3):694-700.
  23. Hirst J, Crow JG. Ovarian Cancer Genetics: Subtypes and Risk Factor. *IntechOpen*. 2018;20:47–54.
  24. Henderson J, Webber ES. Screening for Ovarian Cancer : An Updated

- Evidence Review for the U.S Preventive Services Task Force. US: Rockville (MD):Agency for Healthcare Research and Quality; 2018. 157 hal.
25. Mulisya O, Sikakulya F, Mastaki M, Gertrude TJ. The Challenges of Managing Ovarian Cancer in the Developing World. *Case Rep Oncol Med*. 2020;1–4.
  26. Elzarkaa A, Shaalan W, Elemam D, Al. E. Peritoneal cancer index as a predictor of survival in advanced stage serous epithelial ovarian cancer: A prospective study. *J Gynecol Oncol*. 2018;29(4):1–10.
  27. Hidalgo J, Llueca A, Zolfaroli I, Veiga N, Ortiz EA. Comparison of IOTA three-step strategy and logistic regression model LR2 for discriminating between benign and malignant adnexal masses. *Med Ultrason*. 2021;23(2):168–75.
  28. Sharma B, Arora N, Acharya R, Gupta V, Sharma A, Saxena N, et al. Evaluation of simple International ovarian tumor analysis ultra sound rules in differentiating between benign and malignant ovarian tumors and their histopathological correlation. 2020;
  29. Moro F, Verdecchia V, Romeo P, Ciccarone F, Zannoni G, Valentin L, et al. Ultrasound, macroscopic and histological features of malignant ovarian tumors. *Int J Gynecol Cancer*. 2021;31(1):150–1.
  30. Froyman W, Wynants L, Landolfo C, Bourne T, Valentin L, Testa A, et al. Validation of the performance of International Ovarian Tumor Analysis (IOTA) methods in the diagnosis of early stage ovarian cancer in a non-screening population. *Diagnostics*. 2017;7(2):32.
  31. Abramowicz JT. Ovarian mass—differentiating benign from malignant: The value of the International Ovarian Tumor Analysis ultrasound rules. *Am J Obs Gynecol*. 2017;217(6):652–60.
  32. Society AC. Ovarian Cancer Causes, Risk Factors and Prevention. In 2020.
  33. Bharwani N, Reznick RH, Rockall A. Ovarian Cancer Management: The Role of Imaging and Diagnostic Challenges. *Eur J Radiol*. 2018;78(1):41–51.
  34. Tolani A, Anandan N, Bhuskute NK. Relevance of International Ovarian



- Tumor Analysis (IOTA) ultrasound rules and ADNEX risk calculator in the investigation of ovarian masses in a semi rural Indian population. *Trop J Obs Gynaecol*. 2020;37(1):23–6.
35. Vázquez-Manjarrez S, Rico-Rodriguez O, Guzman-Martinez N, Espinoza-Cruz V L. Imaging and diagnostic approach of the adnexal mass: What the oncologist should know. *Chinese Clin Oncol*. 2020;9(5).
36. Ping He, Jing-jing Wang, Wei Duan, Chao Song, Yu Yang Q qing W. Estimating the risk of malignancy of adnexal masses: validation of the ADNEX model in the hands of nonexpert ultrasonographers in a gynaecological oncology centre in China. 2021;
37. Chen H, Qian L, Jiang M, Du Q, Yuan F, Feng W. Performance of IOTA ADNEX model in evaluating adnexal masses in a gynecological oncology center in China. *Ultrasound Obs Gynecol*. 2019;54:815–22.
38. Dakhly D, Gaafar H, Sediek M, Ibrahim MM. Diagnostic value of the International Ovarian Tumor Analysis (IOTA) simple rules versus pattern recognition to differentiate between malignant and benign ovarian masses. *Int J Gynecol Obs*. 2019;147(3):344–9.
39. Shetty J, Saradha A, Pandey D, Bhat R, Kumar PB. IOTA simple ultrasound rules for triage of adnexal mass: Experience from South India. *J Obs Gynecol India*. 2019;69(4):356–62.
40. Subapriya S. The Past, Present, and Future of Diagnostic Imaging in Ovarian Cancer. *Intech Open*. 2018;175–95.
41. Solanki V, Singh P, Sharma C, Ghuman N, Sureka B, Shekhar S, et al. Predicting malignancy in adnexal masses by the international ovarian tumor analysis-simple rules. *J Midlife Heal*. 2020;11(4):217–23.
42. Soong T, Dinulescu D, Xian WC. Frontiers in the pathology and pathogenesis of ovarian cancer: Cancer Precursors and Precursors Escape. *Hematol Oncol Clin N Am*. 2018;32:915–28.
43. Rodrigues A, Negrão L, Águas FM. Performance of ultrasound models in diagnosis of Ovarian Cancer: Experience of a Portuguese tertiary center. *Acta Obs Ginecol Port*. 2020;14(3):146–54.
44. Jung S. Ultrasonography of ovarian masses using a pattern recognition

- approach. *Ultrasonography*. 2015;34(3):173–82.
45. Zhang, Al. E. Comparion of Gi-Rads Ultrasonographic Stratification and IOTA Simple Rules in Distinguisihing Benign Ovarian Masses from Malignant Ones. *Int J Med Res Heal Sci*. 2019;8(5):75–85.
46. Feharsal Y, Putra A. International Ovarian Tumor Analysis (IOTA) Scoring System to Predict Ovarian Malignancy Pre-operatively. *Indones J Obs Gynecol*. 2016;1:42-6.
47. Garg S, Kaur A, Mohi J, Sibia P, Kaur N. Evaluation of IOTA Simple Ultrasound Rules to Distinguish Benign and Malignant Ovarian Tumours. *J Clin Diagnostic Res*. 2017;11(8):6–10.
48. Butureanu T, Socolov D, Matasariu D, Ursache A, Apetrei A, Dumitrascu I, et al. Ovarian Masses-Applicable IOTA ADNEX Model versus Morphological Findings for Accurate Diagnosis and Treatment. *Appl Sci*. 2021;11:1–11.
49. Anne M, Rea D. Comparison of Accuracy of Gynecologic Ultrasound with IOTA scoring, Frozen Section, Intraoperative Gross Assessment of the Specimen and Routine Histopathology Report in Diagnosing Ovarian Malignancy: A Retrospective Cross-Sectional Analytic Study. Manila: University Medical Center; 2016.
50. Jackson C, Finikarides L, Freeman A. The Adverse Effects of Trastuzumab-containing Regimes as a Therapy in Breast Cancer: A Piggy-back Systematic Review and Meta-analysis. *PLoS One* [Internet]. 2022;17(12):e0275321. Tersedia pada: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714930/pdf/pone.0275321.pdf>
51. Cortez AJ, Tudrej P, Kujawa KA, Lisowska KM. Advances in ovarian cancer therapy. *Cancer Chemother Pharmacol*. 2018;81:17–38.
52. Orr B, Edwards RP. Diagnosis and Treatment of Ovarian Cancer. *Hematol Oncol Clin N Am*. 2018;32:943–64.
53. ESGE, ESHRE, WES, Saridogan E, Becker CM, Feki A, et al. Recommendations for the Surgical Treatment of Endometriosis . Part 1 : *Hum Reprod Open*. 2017;1–6.

54. Tinelli R, Tinelli A, Tinelli FG, Cicinelli E, Malvasi A. Conservative surgery for borderline ovarian tumors: A review. *Gynecol Oncol*. 2006;100:185–91.
55. Savasi I, Lacy JA, Gerstle JT, Stephens D, Kives S, Allen L. Original Study Management of Ovarian Dermoid Cysts in the Pediatric and Adolescent Population. *J Pediatr Adolesc Hynecol*. 2009;22:360–4.
56. Mills AM, Shanes ED. M u c i n o u s O v a r i a n T u m o r s. *Surg Pathol*. 2019;12:565–85.
57. Brown J, Frumovitz M. Mucinous Tumors of the Ovary : Current Thoughts on Diagnosis and Management. *Curr Oncol Rep*. 2014;16:389.
58. Nasioudis D, Mastroyannis SA, Latif NA, Ko EM. Trends in the surgical management of malignant ovarian germ-cell tumors. *Gynecol Oncol*. 2020;xxx(xxxx):5–9.
59. Grogan S, Mount C, Grogan S, Mount C. Ultrasound Physics and Instrumentation. [Internet]. Treasure Island (FL): StatPearls Publishing; Tersedia pada: <https://www.ncbi.nlm.nih.gov/books/NBK570593/>
60. Gottesfeld KR. Ultrasound in Obstetrics and Gynecology. *Semin Roentgenol*. 1975;X(4).
61. Solanki V, Singh P, Sharma C, Ghuman N, Sureka B, Shekhar S, et al. Predicting malignancy in adnexal masses by the international ovarian tumor analysis-simple rules. *J Midlife Health*. 2020;11(4):217–23.
62. Kurjak A, Ph D, Kupesic S, Ph D, Anic T, Ph D, et al. Three-Dimensional Ultrasound and Power Doppler Improve the Diagnosis of Ovarian Lesions. *Gynecol Oncol*. 2000;76:28–32.
63. Furuya M. Ovarian Cancer Stroma: Pathophysiology and the Roles in Cancer Development. *Cancers (Basel)*. 2012;701–24.
64. Rickard BP, Conrad C, Sorrin AJ, Ruhi MK, Reader JC, Huang SA, et al. Malignant Ascites in Ovarian Cancer : Cellular , Acellular , and Therapy Response. *Cancers (Basel)*. 2021;13:4318.
65. Outwater EK, Huang AB, Capuzzi DM, Dunton CJ. Papillary Projections in Ovarian Neoplasms : Appearance on MRI. *JMRI*. 1997;7(4):689–95.
66. Taylor EC, Irshaid L, Mathur M. Multimodality Imaging Approach to



- Ovarian Neoplasms with Pathologic Correlation. *radiographic.rsna.org*. 2019;41(1):1–27.
67. Maly Z, Riss P, Deutinger J. Localization of Blood Vessels and Qualitative Assessment of Blood Flow in Ovarian Tumors. *Obstet Gynecol*. 1995;85(1):33–6.
68. Yoeli-bik R, Lengyel E, Mills KA, Abramowicz JS. Ovarian Masses. *J Ultrasound Med*. 2023;42:935–45.
69. Moro F, Baima P, Zannoni A, Vidal U, Pasciuto M, Ludovisi M, et al. Imaging in gynecological disease (12): clinical and ultrasound features of invasive and non-invasive malignant serous ovarian tumors. *Ultrasound Obstet Gynecol*. 2017;50(6):788–99.
70. Fischerova D, Al E. Yolk Sac Tumor of the Omentum: A Case Report and Literature Review. *Diagnostics* [Internet]. 2022;12(2):304. Tersedia pada: <https://www.mdpi.com/2075-4418/12/2/304>
71. Nunes N, Ambler G, Foo X, Naftalin J, Widschwendter M JD. Use of IOTA simple rules for diagnosis of ovarian cancer: Meta-analysis. *Ultrasound Obs Gynecol*. 2014;4(2):101.
72. Babacar B, Jacque R, Moussa D, Reda J, Abdoul, Aziz Diouf, Bernard B, Bruno C. Management of Ovarian Cystic Tumor: Diagnosis, Management, and Its Follow-Up-Case Presentation of Three Patients and Literature Review. *Open J Obstet Gynecol*. 2020;10(1).
73. Verdecchia V, Al. E. Ultrasound, macroscopic and histological features of borderline ovarian tumors. *Int J Gynecol Cancer*. 2020;0:1–2.
74. Ciccarone F, Codecà C, Versace V, Al. E. Ultrasound, macroscopic and histological features of malignant ovarian tumors. Metastatic tumors to the ovary: ovarian metastases from biliary tract and ovarian metastases from colon cancer. *Int J Gynecol Cancer*. 2021;31:1388–1390.
75. Kheiri SA, Kunna A, Babiker AY, Alsuhailbani SA, Ahmed RY, Alsammani MA. Histopathological Pattern and Age Distribution, of Malignant Ovarian Tumor among Sudanese Ladies. *Open Access Maced J Med Sci*. 2018;6(2):237-241.
76. Koninckx PR, Ussia A, Wattiez A, Adamyan L, Martin DC, Gordts S. The

- severity and frequency distribution of endometriosis subtypes at different ages: a model to understand the natural history of endometriosis based on single centre/single surgeon data. *Facts Views Vis Obgyn*. 2021;13(3):209-219. doi:10.52054/FVVO.13.3.028
77. Alberg AJ, Moorman PG, Crankshaw S, et al. Socioeconomic Status in Relation to the Risk of Ovarian Cancer in African-American Women: A Population-Based Case-Control Study. *Am J Epidemiol*. 2016;184(4):274-283. doi:10.1093/aje/kwv450
  78. Ellwanger B, Schüler-Toprak S, Jochem C, Leitzmann MF, Baurecht H. Anthropometric factors and the risk of ovarian cancer: A systematic review and meta-analysis. *Cancer Rep (Hoboken)*. 2022;5(11):e1618. doi:10.1002/cnr2.1618
  79. Trudel-Fitzgerald C, Poole EM, Idahl A, et al. The Association of Work Characteristics With Ovarian Cancer Risk and Mortality. *Psychosom Med*. 2017;79(9):1059-1067. doi:10.1097/PSY.0000000000000464
  80. Smolarz B, Szyłło K, Romanowicz H. Endometriosis: Epidemiology, Classification, Pathogenesis, Treatment and Genetics (Review of Literature). *Int J Mol Sci*. 2021;22(19):10554. Published 2021 Sep 29. doi:10.3390/ijms221910554
  81. Ovarian Tumors: A Distribution Pattern in a Tertiary Care Center. *Cureus* 15(4): e38273. DOI 10.7759/cureus.38273
  82. Farag NH, Alsaggaf ZH, Bamardouf NO, et al. The Histopathological Patterns of Ovarian Neoplasms in Different Age Groups: A Retrospective Study in a Tertiary Care Center. *Cureus*. 2022;14(12):e33092. Published 2022 Dec 29. doi:10.7759/cureus.33092
  83. Babaier A, Ghatage P. Mucinous Cancer of the Ovary: Overview and Current Status. *Diagnostics*. 2020; 10(1):52. <https://doi.org/10.3390/diagnostics10010052>
  84. Daniilidis A, Grigoriadis G, Dalakoura D, D'Alterio MN, Angioni S, Roman H. Transvaginal Ultrasound in the Diagnosis and Assessment of Endometriosis-An Overview: How, Why, and When. *Diagnostics (Basel)*. 2022;12(12):2912. Published 2022 Nov 23.



doi:10.3390/diagnostics12122912

85. de Oliveira JGA, Bonfada V, Zanella JFP, Coser J. Transvaginal ultrasound in deep endometriosis: pictorial essay. *Radiol Bras.* 2019;52(5):337-341. doi:10.1590/0100-3984.2018.0019
86. Cohen Ben-Meir L, Mashiach R, Eisenberg VH. External Validation of the IOTA Classification in Women with Ovarian Masses Suspected to Be Endometrioma. *J Clin Med.* 2021;10(13):2971. Published 2021 Jul 1. doi:10.3390/jcm10132971
87. Yoeli-Bik R, Longman RE, Wroblewski K, Weigert M, Abramowicz JS, Lengyel E. Diagnostic Performance of Ultrasonography-Based Risk Models in Differentiating Between Benign and Malignant Ovarian Tumors in a US Cohort. *JAMA Netw Open.* 2023;6(7):e2323289. Published 2023 Jul 3. doi:10.1001/jamanetworkopen.2023.23289
88. Virgilio BA, De Blasis I, Sladkevicius P, et al. Imaging in gynecological disease (16): clinical and ultrasound characteristics of serous cystadenofibromas in adnexa. *Ultrasound Obstet Gynecol.* 2019;54(6):823-830. doi:10.1002/uog.20277
89. Heremans, R., Valentin, L., Sladkevicius, P., Timmerman, S., Moro, F., Van Holsbeke, C., Epstein, E., Testa, A.C., Timmerman, D. and Froyman, W. (2022), Imaging in gynecological disease (24): clinical and ultrasound characteristics of ovarian mature cystic teratomas. *Ultrasound Obstet Gynecol*, 60: 549-558. <https://doi.org/10.1002/uog.24904>
90. Abdullahi Idle S, Hayes K, Ross JA. Ultrasound features of immature ovarian teratomas: Case series and review of literature. *Ultrasound.* 2020;28(2):82-90. doi:10.1177/1742271X19895538
91. Moro F, Zannoni GF, Arciuolo D, et al. Imaging in gynecological disease (11): clinical and ultrasound features of mucinous ovarian tumors. *Ultrasound Obstet Gynecol.* 2017;50(2):261-270. doi:10.1002/uog.17222
92. Weerakkody Y, Niknejad M, Shah V, et al. Ovarian mucinous cystadenoma. Reference article, Radiopaedia.org (Accessed on 28 Sep 2024) <https://doi.org/10.53347/rID-13390>

93. Moro F, Castellano LM, Franchi D, et al. Imaging in gynecological disease (22): clinical and ultrasound characteristics of ovarian embryonal carcinomas, non-gestational choriocarcinomas and malignant mixed germ cell tumors. *Ultrasound Obstet Gynecol.* 2021;57(6):987-994. doi:10.1002/uog.23529
94. Kurniadi A, Permadi W, Kusuma AY, Kireina J, Andarini MY, Winarno GNA, Harsono AB. Performance of Pre-Operative IOTA Three-Step Algorithm in Detecting Ovarian Carcinoma in a Referral Center in Indonesia. *Indonesian Journal of Cancer.* 2024; 18(1): 32–35
95. Minh DT, Nguyet et al. IOTA simple rules: An efficient tool for evaluation of ovarian tumors by non-experienced but trained examiners - A prospective study. *Heliyon*, 2024; 10(2): e24262
96. Xie WT, Wang YQ, Xiang ZS, et al. Efficacy of IOTA simple rules, O-RADS, and CA125 to distinguish benign and malignant adnexal masses. *J Ovarian Res.* 2022;15(1):15. Published 2022 Jan 23. doi:10.1186/s13048-022-00947-9

